Our novel anti-biofilm strategy aims to address the burden of biofilm-mediated inflammation and progressive lung function. Read more on how we're working to combat chronic respiratory conditions.Our Science Meet our team: a strategically focused group of experts with deep therapeutic and vaccine development expertise.Meet The Team In the News Clarametyx Biosciences Strengthens Leadership Team to Accelerate Pipeline and Corporate Development ProgressOctober 20, 2025 Clarametyx Biosciences Announces Completion of Enrollment in Phase 2a Study of CMTX-101 in Cystic FibrosisOctober 16, 2025 Clarametyx Biosciences Announces FDA Grant Of Fast Track And Qualified Infectious Disease Product Designations For CMTX-101August 4, 2025 Clarametyx Biosciences Announces Positive Interim Analysis in Phase 2a Study Evaluating CMTX-101 for Infections Associated with Cystic FibrosisJune 16, 2025